Sam Chun Dang Pharm was designated as an unfaithful disclosure corporation by the Korea Exchange (KRX).
On the 20th, the KOSDAQ Market Division of the Korea Exchange (KRX) disclosed that it designated Sam Chun Dang Pharm as an unfaithful disclosure corporation for "failure to implement fair disclosure of outlook or forecasts on business performance, etc." and imposed 5 demerit points.
The Korea Exchange (KRX) had announced on the 31st that it would designate Sam Chun Dang Pharm as an unfaithful disclosure corporation, noting that a disclosure committee composed of external experts would deliberate, taking into account the motive and significance of Sam Chun Dang Pharm's disclosure violation.
If demerit points accumulate, the corporation may be designated as an issue under management by the Korea Exchange (KRX). If a similar case recurs after the designation, it becomes subject to a substantive review for delisting.
The Korea Exchange (KRX) said that in the case of Sam Chun Dang Pharm, the total demerit points imposed in relation to the designation as an unfaithful disclosure corporation over the past year amount to 5, including this action.